Compare FDC with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 5,763 Cr (Small Cap)
19.00
37
1.41%
-0.20
11.98%
2.32
Total Returns (Price + Dividend) 
Latest dividend: 5 per share ex-dividend date: Feb-11-2026
Risk Adjusted Returns v/s 
Returns Beta
News

MarketsMOJO Downgrades FDC Ltd to Sell Amid Mixed Financials and Bearish Technicals
FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Aug 2026. The downgrade reflects a combination of deteriorating technical indicators, subdued long-term financial growth, and waning institutional interest, despite recent quarterly earnings improvements.
Read full news article
FDC Ltd Faces Technical Downshift Amidst Prolonged Underperformance
FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, signalling a transition from a sideways trend to a mildly bearish outlook. This change is underscored by deteriorating momentum indicators and mixed signals from key technical tools, prompting a downgrade in its Mojo Grade from Hold to Sell as of 17 Aug 2026.
Read full news article
FDC Ltd Technical Momentum Shifts Amid Mixed Market Signals
FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators present a mixed picture, with bearish signals dominating monthly charts while daily moving averages suggest mild bullishness. This article analyses the evolving price momentum, key technical indicators, and the implications for investors amid a challenging market backdrop.
Read full news article Announcements 
Grant Of Marketing Authorisation From MHRA UK For Atropine 1.0% W/V Eye Drops Solution.
13-Aug-2026 | Source : BSEThis is to inform you that the companys Subsidiary FDC International Ltd. has received Marketing Authorisation from the MHRA UK for Atropine 1.0% w/v Eye Drops Solution.
Board Meeting Outcome for Board Meeting Outcome For Outcome For The Board Meeting Held On August 05 2026.
05-Aug-2026 | Source : BSEOutcome for the Board Meeting Held on 5th August 2026.
Financial Results For The Quarter Ended June 30 2026
05-Aug-2026 | Source : BSEFinancial Results for the quarter ended June 30 2026
Corporate Actions 
No Upcoming Board Meetings
FDC Ltd has declared 500% dividend, ex-date: 11 Feb 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 5 Schemes (6.25%)
Held by 74 FIIs (1.4%)
Nomita R Chandavarkar (22.67%)
Icici Prudential Smallcap Fund (2.8%)
17.64%
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 14.18% vs 25.84% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 28.13% vs 265.37% in Mar 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024
Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -1.86% vs 9.14% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -21.96% vs -11.90% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 2.98% vs 8.50% in Mar 2025
YoY Growth in year ended Mar 2026 is 5.48% vs -12.59% in Mar 2025






